Pancratic cancer is the eighth most common cancer and the fifth most common cause of cancer-related deaths in Korea. Despite the increasing incidence and high mortality rate of pancreatic cancer, there are no appropriate surgical practice guidelines for the current domestic medical situation. To enable standardization of management and facilitate improvements in surgical outcome, a total of 10 pancreatic surgical experts who are members of Korean Association of Hepato-Biliary-Pancreatic Surgery have developed new recommendations that integrate the most up-to-date, evidence-based research findings and expert opinions. This is an English version of the Korean Surgical Practice Guideline for Pancreatic Cancer 2022. This guideline includes 13 surgical questions and 15 statements. Due to the lack of high-level evidence, strong recommendation is almost impossible. However, we believe that this guideline will help surgeons understand the current status of evidence and suggest what to investigate further to establish more solid recommendations in the future.

**Key Words:** Pancreatic carcinoma; Surgery; Practice guideline

**INTRODUCTION**

Pancreatic cancer is the eighth most common cancer (with an annual new case number of approximately 7,000 in 2017) and the fifth most common cause of cancer-related death in South Korea [1]. The incidence and mortality of pancreatic cancer have increased gradually with a 5-year relative survival rate of 12.2% in 2017 with nearly no improvements in this figured over the last 20 years.

Despite the increasing incidence and high mortality rate of pancreatic cancer, there are no appropriate surgical practice guidelines for the current domestic medical situation regarding this cancer. Various practice guidelines for pancreatic cancer
have been established and reported [2-4]. However, none of them has provided detailed guidelines for surgical procedures. Although Korean Clinical Practice Guidelines for Pancreatic Cancer 2021 has been published, only a limited number of surgical issues have been addressed [5]. Thus, surgeons in the committee of the Korean Clinical Practice Guideline for Pancreatic Cancer 2021 gathered and tried to establish a surgical practice guideline.

This guideline was designed to provide adequate surgical information and stimulate research to build evidence for the treatment of pancreatic cancer including 13 surgical questions and 15 statements. Among these 13 questions, four questions were extracted from the Korean clinical practice guidelines for pancreatic cancer 2021 with the addition of a few new references [5]. It is very difficult to obtain high-level evidence for the management of pancreatic disease, especially surgical management of pancreatic cancer. The low number of cases is insufficient to undertake a randomized controlled trial (RCT). The technique is too complicated to be standardized. In addition, technical issues are rapidly changing and supportive groups for clinical studies about surgery are rare. High-level evidence and strong recommendations are almost impossible. However, we believe that this guideline will help surgeons understand the current status of evidences and suggest direction for further studies to establish more solid recommendations.

**GUIDELINE DEVELOPMENT METHODOLOGY**

This surgical guideline primarily targets adult patients with suspected or newly diagnosed pancreatic ductal adenocarcinoma. This guideline is intended to provide useful surgical information and directions for all surgeons. It was developed by members of the Korean Association of Hepato-Biliary-Pancreatic Surgery. To complete this guideline, we established a development working group and a review panel for Korean Surgical Practice Guideline for Pancreatic Cancer 2022.

The process of new guideline development was as follows: (1) selecting clinical key questions (KQs), (2) determining development methods, (3) performing literature search and selection, (4) assessing the quality of the selected literature and synthesizing evidence, (5) determining the levels of evidence and strength of recommendations, and (6) providing statements for clinical questions.

Clinical KQs were specified by considering the population, intervention/index test, comparator, and outcome (PICO) elements. This guideline is the first Korean surgical practice guideline for pancreatic cancer. It was developed by de novo methods.

We systematically searched published literature using databases including Medline, Embase, Cochrane Library, and KoreaMed through May 2021. For the adaptation method, additional databases including the Guideline International Network and Korean Clinical Practice Guideline Information Center were searched. Manual searches were also performed to complement and update the results. Inclusion and exclusion criteria were determined by panels composed of pairs of clinical experts. These inclusion and exclusion criteria were predefined and tailored to KQs. Articles were screened by title and abstract. Full texts were then retrieved for selection. In each step, two panels performed selections independently. Agreements were reached.

We critically appraised the quality of selected studies using

| Table 1. Levels of evidence |
|----------------------------|
| **Level** | **Explanation** |
| **High** | Study design |
| | (Intervention) Results from randomized controlled trials or comparative designed observational studies. |
| | (Diagnosis) Results from randomized controlled trials or diagnostic accuracy tests with a cross-sectional cohort design. |
| Considerations: There are no concerns regarding the methodological assessment or the consistency or precision of the results. |
| The certainty of evidence is high for the synthesized result. |
| **Moderate** | Study design |
| | (Intervention) Results from randomized controlled trials or comparative designed observational studies. |
| | (Diagnosis) Results from randomized controlled trials or diagnostic accuracy tests with a cross-sectional cohort design. |
| Considerations: There are minor concerns regarding the methodological assessment or the consistency or precision of the results. |
| The certainty of evidence is moderate for the synthesized result. |
| **Low** | Study design |
| | (Intervention) Results from observational studies with or without comparison groups. |
| | (Diagnosis) Results from diagnostic accuracy tests with a case-controlled design. |
| Considerations: There are serious concerns regarding the methodological assessment or the consistency or precision of the results. |
| The certainty of evidence is low for the synthesized result. |
| **Very low** | Study design |
| | (Intervention) Results from observational studies without comparison groups or experts’ opinions. |
| | (Diagnosis) Results from diagnostic accuracy tests with a case-controlled design. |
| Considerations: There are very serious concerns regarding the methodological assessment or the consistency or precision of the results. The certainty of evidence is very low for the synthesized result. |

https://doi.org/10.14701/ahbps.22-009
risk-of-bias tools. We used Cochrane risk of bias (ROB) for RCTs, risk of bias for nonrandomized studies (RoBANS), and a measurement tool to assess systematic reviews (AMSTAR) for systematic reviews/meta-analyses [6-9]. Disagreements were resolved by discussion and seeking the opinion of a third member. We extracted data using a predefined format and synthesized the data qualitatively or quantitatively. Evidence tables were summarized according to KQs. In the adaptation method, we assessed the quality using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument for evaluating the currency, acceptability, and applicability of medical guidelines [10,11].

Levels of evidence and grading of recommendations were modified based on the Scottish Intercollegiate Guidelines Network (SIGN) and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology reviews [12,13]. The evidence was classified into four levels (Table 1). Main factors were the study design and quality. In addition, we considered outcome consistency. The grading of recommendations was performed according to the modified GRADE methodology. It had four levels (Table 2). Recommendation factors considered were evidence level, balance of benefit and harm, and clinical applicability (resource and cost). The Development Working Group reviewed the draft and discussed the consensus. The Review Panel examined the final version of the draft through careful expert review. The guideline developed through this process was then endorsed by an open meeting of the Korean Pancreas Surgery Club. Revisions were made in accordance with suggestions at the open meeting. This guideline will be revised every five years when there is solid evidence that can affect outcomes of patients with pancreatic cancer.

### RECOMMENDATIONS (Table 3)

**Staging laparoscopy**

**KQ 1: Is staging laparoscopy routinely indicated in resectable pancreatic cancer (RPC)?**

**Recommendation 1:** Staging laparoscopy could be considered selectively before laparotomy in patients with RPC

(Strength of recommendation: Conditional; Level of evidence: Low)

**Comments:** In retrospective cohort studies, diagnostic laparoscopy was effective in terms of decreasing cost and reducing unnecessary laparotomy by detecting occult metastases [14-18]. In addition, patients with staging laparoscopy received chemotherapy earlier than those with occult metastasis found during laparotomy, leading to improved survival [14,19]. However, the false-negative rate of staging laparoscopy was higher than that of exploratory laparotomy [15]. Therefore, careful observation is required during staging laparoscopy. According to a meta-analysis, staging laparoscopy could detect occult metastases not found in preoperative images in 14%–38% of patients with RPCs and 36% of those with locally advanced pancreatic cancer (LAPC) [20].

With improvement in preoperative imaging examinations such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), selective staging laparoscopy has been suggested [21,22]. However, evidence for the potential criteria for selective staging laparoscopy is still limited. A well-designed prospective multicenter randomized study on the effectiveness of staging laparoscopy is needed.

| Table 2. Grading of recommendations |   |
|-------------------------------------|---|
| Strength of recommendations         | Explanation                        |
| Strong recommendation               | The intervention/diagnostic test can be strongly recommended in most clinical practice, considering greater benefit than harm, evidence level, value and preference, and resources. |
| Conditional recommendation           | The intervention/diagnostic test can be conditionally recommended in clinical practice considering the balance of benefit and harm, evidence level, value and preference, and resources. |
| Not recommended                     | The harm caused by the intervention/diagnostic test may be greater than its benefits. Moreover, considering the evidence level, value and preference, and resources, the intervention should not be recommended. |
| Inconclusive                        | It is not possible to determine the strength and direction of recommendation because of a very low or insufficient evidence level, uncertain or variable balance of benefit and harm, value and preference, and resources. |
Minimally invasive surgery (MIS)

**KQ 2: Is MIS applicable to patients with RPC?**

**Recommendation 2: MIS could be performed selectively for patients with RPC by highly experienced surgeons**

(Strength of recommendation: Conditional; Level of evidence: Low)

Comments:

1) Pancreatoduodenectomy (PD)

There was no difference in postoperative complication rate between MIS and open surgery for PD [23-28]. Their reported 30-day mortality rates were also similar [24-29]. Median survival durations after MIS and open surgery of PD were comparable in six studies [23-28]. Zhou et al. [28] have reported better survival in open surgery. However, this difference did not persist after propensity-score matching (Table 4) [28]. Four meta-analyses have found no differences in complications, mortality, or survival between MIS and open surgery for PD [30-33]. However, selection bias requires cautious interpretation of these findings.

---

**Table 3. Summary of key questions and recommendations**

| Key question and recommendation | Strength of recommendation | Level of evidence |
|---------------------------------|-----------------------------|-------------------|
| KQ 1. Is staging laparoscopy routinely indicated in resectable pancreatic cancer (RPC)? | Conditional | Low |
| Recommendations: Staging laparoscopy could be considered selectively before laparotomy in patients with RPC. | Conditional | Low |
| KQ 2. Is minimally invasive surgery (MIS) applicable to the patients with RPC? | Conditional | Low |
| Recommendations: MIS could be performed selectively for the patients with RPC by highly experienced surgeons. | Conditional | Low |
| KQ 3. Is extended lymph node dissection (LND) and nerve plexus dissection necessary during pancreaticoduodenectomy (PD) for the patients with resectable pancreatic head cancer (RPHC)? | Not recommend | High |
| Recommendations: Extended LND is not recommended for the patients with RPHC. | Conditional | Low |
| KQ 4-1. Is combined portal vein (PV) or superior mesenteric vein (SMV) resection beneficial in patients with pancreatic cancer invading the PV or SMV? | Not recommend | Low |
| Recommendations: PV or SMV resection could be considered if radical resection is possible in patients with pancreatic cancer invading the PV or SMV. | Conditional | Low |
| KQ 4-2. Is superior mesenteric artery (SMA) resection beneficial in patients with pancreatic cancer invading the SMA? | Not recommend | Low |
| Recommendations: SMA resection is not recommended in patients with pancreatic cancer invading the SMA. | Conditional | Low |
| KQ 4-3. Is distal pancreatectomy with celiac axis resection (DP-CAR) beneficial in patients with pancreatic cancer invading the celiac axis (CA)? | Conditional | Low |
| Recommendations: DP-CAR could be considered, if radical resection is possible in patients with pancreatic cancer invading the CA. | Conditional | Low |
| KQ 5. Is mesopancreas excision (MpE) beneficial during PD? | Conditional | Low |
| Recommendations: MpE could be considered to improve the rate of R0 resection for the patients with RPHC. | Conditional | Low |
| KQ 6. Is pylorus preserving pancreaticoduodenectomy (PPPD) preferred to PD in RPHC? | Conditional | High |
| Recommendations: PPPD is preferred to PD in RPHC. | Conditional | Low |
| KQ 7. Is additional pancreas resection necessary in cases of positive pancreatic resection margin in intraoperative frozen biopsy? | Not recommend | Low |
| Recommendations: Additional pancreas resection could be considered if pancreatic resection margin is positive in intraoperative frozen biopsy. | Conditional | Low |
| KQ 8. Is radical antegrade modular pancreatosplenectomy (RAMPS) beneficial in pancreatic body or tail cancer? | Conditional | Low |
| Recommendations: RAMS could be considered in pancreatic body or tail cancer. | Conditional | Low |
| KQ 9. Is bypass gastrojejunostomy necessary in cases of unresectable pancreatic cancer without gastric outlet obstruction? | Not recommend | Low |
| Recommendations: Bypass gastrojejunostomy is not recommended in patients with unresectable pancreatic cancer without gastric outlet obstruction. | Conditional | Low |
| KQ 10. Is pancreactectomy beneficial in cases of pancreatic cancer with pathologically proven para-aortic lymph node metastasis in intraoperative frozen biopsy? | Inconclusive | Very low |
| Recommendations: Recommendation to perform pancreactectomy in cases of pancreatic cancer with pathologically proven para-aortic lymph node metastasis in intraoperative frozen biopsy is withheld. | Inconclusive | Very low |
| KQ 11. Is hepatic resection beneficial in cases of pancreatic cancer with hepatic oligometastasis? | Inconclusive | Very low |
| Recommendations: Recommendation to perform hepatic resection in cases of pancreatic cancer with hepatic oligometastasis is withheld. | Inconclusive | Very low |
| KQ 12. Is conversion surgery beneficial in cases of locally advanced pancreatic cancer (LAPC)? | Conditional | Low |
| Recommendations: Conversion surgery after induction chemotherapy could be considered in cases of LAPC. | Conditional | Low |
| KQ 13. Is artery first approach in pancreaticoduodenectomy (AFA-PD) beneficial in cases of pancreatic head cancer? | Inconclusive | Very low |
| Recommendations: Recommendation to perform AFA-PD in cases of pancreatic head cancer is withheld. | Inconclusive | Very low |
2) Distal pancreatectomy (DP)

Five studies have reported comparable or better complication rates and postoperative mortality rates of MIS versus open surgery for DP [25,34-37]. Long-term survival rates were comparable between MIS and open surgery for DP [25,36-39]. Survival benefit of MIS has been demonstrated in two studies (Table 5) [34,35]. In one meta-analysis, there were no differences in complication rates, severe complication rates, postoperative mortality rates, or long-term survival rates between MIS and open surgery for DP [40].

MIS PD and has comparable short- and long-term outcomes with open surgery and has the advantage of reducing pain, blood transfusion, and hospital stay. In particular, faster recovery after MIS may be a significant advantage for patients who require postoperative adjuvant treatment. However, since MIS is a complex and difficult surgical procedure, radical resection of the tumor and patient safety might not be guaranteed when this procedure is performed by under-experienced surgeons.

Although the literature indicated comparable or better results of MIS versus open surgery in terms of postoperative morbidity and mortality as well as long-term survival, these findings were derived from retrospective data with possible selection bias.

### Table 4. Summary of retrospective cohort studies of pancreaticoduodenectomy

| Author              | Comparison group          | Number | Morbidity rate (%) | p-value | 30-day mortality (%) | p-value | Median survival (mon) | p-value |
|---------------------|---------------------------|--------|--------------------|---------|----------------------|---------|-----------------------|---------|
| Adam et al. (2015)  | Laparoscopy/robot         | 831    | N/A                | -       | 42 (5.1)             | 0.10    | N/A                   | -       |
|                     | Open                      | 5,235  |                    |         | 199 (3.8)            |         |                       |         |
| Choi et al. (2020)  | Laparoscopy               | 27     | 10 (37.0)          | 0.700   | N/A                  | 44.62   | 0.223                 |         |
|                     | Open                      | 34     | 10 (29.4)          |         | 45.29                |         |                       |         |
| Croome et al. (2014)| Laparoscopy               | 108    | 6 (5.6)            | 0.17    | 1 (0.9)              | 0.50    | 25.3                  | 0.12    |
|                     | Open                      | 214    | 29 (13.6)          |         | 4 (1.9)              |         | 21.8                  |         |
| Girgis et al. (2021)| Laparoscopy               | 163    | 40 (24.5)          | 0.265   | 3 (1.8)              | 1.00    | 25.6                  | 0.055   |
|                     | Robot                     | 198    | 59 (29.8)          |         | 3 (1.5)              |         | 23.9                  |         |
| Kuesters et al. (2018)| Laparoscopy             | 62     | 25 (40.3)          | 0.81    | 3 (4.8)              | 0.23    | 20%                   | 0.51    |
|                     | Open                      | 278    | 107 (38.5)         |         | 6 (2.2)              |         |                       |         |
| Stauffer et al. (2017)| Laparoscopy            | 58     | 13 (22.4)          | 0.170   | 2 (3.4)              |         | 18.5                  | 0.25    |
|                     | Open                      | 193    | 58 (30.1)          |         | 10 (5.2)             |         | 30.3                  |         |
| Zhou et al. (2019)  | Laparoscopy               | 79     | 9 (11.4)           | 0.333   | 1 (1.3)              | > 0.999 | 18.0                  | 0.032   |
|                     | Open                      | 230    | 18 (7.8)           |         | 2 (0.9)              |         | 22.8                  | (0.293) |

N/A, not available.

Three-year overall survival; includes distal pancreatectomies; S-year survival rate; after propensity score matching analysis.

### Table 5. Summary of retrospective cohort studies of distal pancreatectomy

| Author             | Comparison group          | Number | Morbidity rate (%) | p-value | 90-day mortality (%) | p-value | Median survival (mon) | p-value |
|--------------------|---------------------------|--------|--------------------|---------|----------------------|---------|-----------------------|---------|
| Anderson et al. (2017)| Laparoscopy/robot        | 505    | N/A                | -       | 11 (2.2)             | 0.10    | 55%                   | 0.42    |
|                     | Open                      | 1,302  |                    |         | 43 (3.3)             |         |                       |         |
| Girgis et al. (2021)| Laparoscopy               | 48     | 8 (16.7)           | 0.724   | 3 (6.25)             | 1.00    | 25.6                  | 0.055   |
|                     | Open                      | 25     | 5 (20.0)           |         | 1 (4.0)              |         | 23.9                  |         |
| Kantor et al. (2017)| Laparoscopy               | 349    | N/A                | -       | 9 (3.7)              | 0.26    | 29.9                  | 0.09    |
|                     | Open                      | 1,205  |                    |         | 52 (5.6)             |         |                       |         |
| Lee et al. (2014)   | Laparoscopy/robot         | 12     | 3 (25.0)           | 0.412   | 0 (0)                | 0.484   | 60.0                  | 0.046   |
|                     | Open                      | 78     | 29 (37.2)          |         | 2 (2.6)              |         | 30.7                  |         |
| Sulpice et al. (2015)| Laparoscopy              | 347    | 23 (6.6)           | 0.0284  | 9 (2.6)              | 0.0215  | 62.5                  | < 0.0001|
|                     | Open                      | 2,406  | 251 (10.4)         |         | 135 (5.6)            |         | 36.7                  |         |
| van Hilst et al. (2019)| Laparoscopy             | 340    | 61 (17.9)          | 0.431   | 7 (2.1)              | > 0.999 | 28                    | 0.774   |
|                     | Open                      | 340    | 70 (20.6)          |         | 8 (2.4)              |         | 31                    |         |
| Zhang et al. (2015) | Laparoscopy               | 17     | 6 (35.3)           | 0.754   | 0 (0)                | N/A     | 14.0                  | 0.802   |
|                     | Open                      | 34     | 14 (41.2)          |         | 1 (2.9)              |         | 14.0                  |         |

N/A, not available.

Three-year overall survival; includes pancreateoduodenectomy; postoperative within 30-day mortality.
lection bias. Therefore, the evidence for MIS remains low and MIS cannot be strongly recommended in general. MIS may be performed for well-selected patients with pancreatic cancer by highly experienced expert surgeons in MIS.

**Extended lymph node dissection (LND)**

**KQ 3: Is extended LND and nerve plexus dissection necessary during PD for patients with resectable pancreatic head cancer (RPHC)?**

**Recommendation 3: Extended LND is not recommended for patients with RPHC**

*(Strength of recommendation: Not recommend; Level of evidence: High)*

**Comments:** Five RCTs have reported increased postoperative complication and mortality rates after extended LND, albeit not statistically significant [41-45]. Moreover, extended LND did not result in improved survival outcomes. It even led to worse survival outcomes in some studies (Table 6) [43,44,46]. Three meta-analyses also demonstrated that extended LND did not have survival gain [46-48]. Two studies confirmed higher postoperative complication and mortality rates after extended LND, although differences were not statistically significant [47,48].

Extended LND demands a longer operative time and surgeons' effort. It increases the risk of complications and mortality rate without offering any survival benefit. Therefore, an extended LND is not generally recommended. It may be performed in limited cases where widespread lymph node metastasis is highly suspected. However, unnecessary extended LND should be avoided by utilizing frozen biopsy of suspected lymph nodes in fields beyond the standard extent.

**Vascular resection**

**KQ 4-1: Is combined portal vein (PV) or superior mesenteric vein (SMV) resection beneficial in patients with pancreatic cancer invading the PV or SMV?**

**Recommendation 4-1: PV or SMV resection could be considered if radical resection is possible in patients with pancreatic cancer invading the PV or SMV**

*(Strength of recommendation: Conditional; Level of evidence: Low)*

**Comments:** Five meta-analyses have summarized findings for this question [49-53]. Patients who underwent PV/SMV resection tended to have a slightly higher postoperative mortality [49-51] and reoperation rate [49,50,52], lower curative resection rate and survival rate [49-52], longer operative time and hospital stay [49,50,52], and more complications such as pancreatic fistula, delayed gastric emptying, or bleeding than those who received standard pancreatectomy without PV/SMV resection [49,50,52]. Considering that more patients with advanced pancreatic cancer were included in the PV/SMV resection group, the survival rate in the PV/SMV resection group was similar to that in the non-PV/SMV resection group if R0 was achieved. In a study that included only the PV/SMV resection group, curatively resected patients showed better survival than non-curatively resected patients [52].

PV/SMV resection could be beneficial if performed by a highly skilled surgeon to obtain R0 resection and minimize mortality or postoperative complications.

**Table 6. Summary of randomized controlled trials comparing extended lymph node dissection (LND) and standard LND**

| Author          | Comparison group | Number | Morbidity rate (%)<sup>a</sup> | p-value | Postoperative mortality rate (%) | p-value | Survival rate (%) | p-value |
|-----------------|------------------|--------|--------------------------------|---------|---------------------------------|---------|------------------|---------|
| Farnell et al.  | Extended Standard| 39     | N/A                            | NS<sup>a</sup> | 1 (2.6)                         | NS      | 17 (5-yr)         | 0.320 |
| Nimura et al.   | Extended Standard| 50     | 22.0                           | NS      | 1 (2.0)                         | NS      | 6.0 (5-yr)        | 0.119 |
| Jang et al.     | Extended Standard| 86     | 37 (43.0)                      | 0.160   | 2 (2.3)                         | NS      | 35.7 (2-yr)       | 0.122 |
| Jang et al.     | Standard         | 83     | 27 (32.5)                      | 0.160   | 2 (2.3)                         | NS      | 44.5 (2-yr)       | 0.388 |
| Ignjatovic et al.| Extended Standard| 30     | 1 (3.3)<sup>b</sup>            | 0.05    | 2 (6.7)                         | 0.05    | 7.1 (5-yr)        | 0.057 |
|                 | Standard         | 30     | 0 (0)                          |         | 1 (3.3)                         |         | 6.9 (5-yr)        |         |

N/A, not available; NS, not significant.

<sup>a</sup>Complications were evaluated separately and not as a whole. There were no differences for all sub-specified complications. <sup>b</sup>Postoperative bleeding.

https://doi.org/10.14701/ahbps.22-009
Korean Surgical Practice Guideline for Pancreatic Cancer

KQ 4-2: Is superior mesenteric artery (SMA) resection beneficial in patients with pancreatic cancer invading the SMA?

Recommendation 4-2: SMA resection is not recommended in patients with pancreatic cancer invading the SMA
(Strength of recommendation: Not recommend; Level of evidence: Low)

Comments: Since the SMA is surrounded by numerous lymph nodes and nerve plexuses, radical resection is technically more difficult than PV or SMV resection. Since all reviewed studies included heterogeneous patients who underwent PV, SMV, common hepatic artery, or SMA resection, it was difficult to select and analyze patients who underwent SMA resection [54-59]. Retrospective studies have demonstrated comparable survival rates in SMA resected patients to those in patients without SMA resection [54-56]. However, recently published meta-analyses have shown worse survival rates and higher rates of morbidity and mortality in the SMA resection group than in the non-SMA resection group [57-59]. Therefore, SMA resection should not be generally recommended. Although some surgeons may perform SMA resection in case of showing excellent response after neoadjuvant chemotherapy, further studies focusing on patients who undergo combined SMA resection after neoadjuvant chemotherapy are needed.

KQ 4-3: Is distal pancreatectomy with celiac axis resection (DP-CAR) beneficial in patients with pancreatic cancer invading the celiac axis (CA)?

Recommendation 4-3: DP-CAR could be considered if radical resection is possible in patients with pancreatic cancer invading the CA
(Strength of recommendation: Conditional; Level of evidence: Low)

Comments: DP-CAR is a challenging procedure. It has yielded certain clinical efficacy in the treatment of LAPC invading the CA. However, the clinical efficacy and safety of DP-CAR remain controversial. Median survival rate of DP-CAR group was 17.5–20 months. The survival rate of the DP-CAR group was comparable to that of the DP without CA resection group [60-66], but significantly higher than that of the non-pancreatic resection group [60,62,65]. In meta-analyses, the R0 resection rate of DP-CAR group was 72.8%. The postoperative complication rate of the DP-CAR group was significantly higher than that of the DP group while the hospital mortality rate was comparable [64,65].

DP-CAR is complicated procedure with a high morbidity rate. However, since DP-CAR showed better survival than the non-resected group, DP-CAR could be performed to improve the R0 resection rate and survival rate by highly skilled surgeons for carefully selected patients.

Mesopancreas excision (MpE)

KQ 5: Is MpE beneficial during PD?

Recommendation 5: MpE could be considered to improve the rate of R0 resection for patients with RPHC
(Strength of recommendation: Conditional; Level of evidence: Low)

Comments: Mesopancreas is defined as a firm and well-vascularized structure extending from the posterior surface of the pancreatic head to behind the mesenteric vessels. The concept of MpE in pancreatic head cancer (PHC) was proposed in analogy to the concept of total mesorectal excision for rectal cancer to better control locoregional recurrence by achieving a complete excision of the mesopancreas during PD and to increase R0 resection rate for PHC. In retrospective cohort studies, R0 resection rates of MpE were approximately 90%, significantly higher than those of conventional PD without increasing morbidity [67-69]. Recurrence rate after MpE was significantly lower than that after conventional PD (Table 7) [67,70]. However, MpE did not result in improved survival [68].

Because of low-level evidence derived from a small number of retrospective studies, MpE should not be generally recommended, although MpE is a feasible procedure. It might be

---

Table 7. Summary of retrospective cohort studies of mesopancreas excision (MpE)

| Author          | Comparison group | Number | Morbidity (%) | p-value | R0 (%) | p-value | Recurrence (%) | p-value | 1YSR (%) | p-value |
|-----------------|------------------|--------|---------------|---------|--------|---------|----------------|---------|----------|---------|
| Kawabata et al. [67] | C-PD             | 25     | 56            | 0.546   | 60     | 0.019   | 64             | 0.036   | 48       | N/A     |
|                 | MpE              | 14     | 50            |         | 93     |         | 14             |         | 76       |         |
| Aimoto et al. [70] | C-PD             | 19     | 32            | NS      | 68     | NS      | 37             | < 0.01  | 70       | NS      |
|                 | MpE              | 19     | 47            |         | 74     |         | 0              |         | 60       |         |
| Sugiyama et al. [69] | C-PD             | 45     | 39            | 0.078   | 78     | 0.099   | NA             |         | N/A      |         |
|                 | MpE              | 58     | 28            | 90      |        |         |                |         |          |         |
| Xu et al. [68]  | C-PD             | 43     | 51            | 0.250   | 77     | 0.041   | 55             | 0.054   | 20 mo<sup>a</sup> | 0.176   |
|                 | MpE              | 58     | 40            | 91      |        |         | 32             |         | 23 mo<sup>a</sup> |         |

1YSR, 1-year survival rate; C-PD, conventional pancreaticoduodenectomy; NA, not available; NS, not significant.

<sup>a</sup>Median overall survival.
Performed in limited cases to achieve R0 resection. Further studies with long-term survival data are needed to confirm the benefits of MpE.

Pylorus preserving pancreaticoduodenectomy (PPPD) vs. pancreaticoduodenectomy (PD)

KQ 6: Is PPPD preferred to PD in RPHC?
Recommendation 6: PPPD is preferred to PD in RPHC
(Strength of recommendation: Conditional; Level of evidence: High)
Comments: To date, the debate continues as to whether PPPD or PD is better for periampullary and pancreatic carcinoma. Three RCTs and three meta-analyses have compared PPPD and PD in terms of complications and nutritional status [71-76]. There were no significant differences in postoperative morbidity including pancreatic fistula, postoperative bleeding, or hospital mortality between PPPD and PD groups, although there were controversial results on delayed gastric emptying. For long-term complications including weight loss, dumping syndrome, diarrhea and long-term nutritional status, there were no significant differences between PPPD and PD groups [73,77]. Therefore, both surgical procedures are acceptable for the treatment of pancreatic carcinoma. Surgeons can choose either operative method based on their preferences. If there are no differences in oncological or nutritional aspects, PPPD should be preferred in terms of organ preservation.

Intraoperative frozen biopsy for pancreatic resection margin

KQ 7: Is additional pancreas resection necessary in cases of positive pancreatic resection margin in intraoperative frozen biopsy?
Recommendation 7: Additional pancreas resection could be considered if pancreatic resection margin is positive in intraoperative frozen biopsy
(Strength of recommendation: Conditional; Level of evidence: Low)
Comments: Several reports have compared the survival of patients between those who have undergone an additional resection and finally have negative pancreatic resection margin and those who have not undergone additional resection in spite of positive resection margin or who have positive resection margin after additional pancreatic resection [78-85]. Except for two studies that failed to perform survival analysis due to the small number of included patients [79,82], the remaining retrospective studies showed controversial results in survival outcome [78,80,81,83]. Meta-analysis and systematic review did not demonstrate survival benefit after additional pancreatic resection in giving a negative margin [84,85].

The aggressive biology of pancreatic carcinoma might be associated with the unexpected result that revision of an R1 pancreatic resection margin based on intraoperative frozen biopsy could not improve overall survival. However, considering that obtaining negative resection margin is the principle of surgery in oncology, surgeons should try to perform additional pancreatic resection to achieve a negative resection margin.

Radical antegrade modular pancreatosplenectomy (RAMPS)

KQ 8: Is RAMPS beneficial in pancreatic body or tail cancer?
Recommendation 8: RAMPS could be considered in pancreatic body or tail cancer
(Strength of recommendation: Conditional; Level of evidence: Low)
Comments: In 2003, Strasberg et al. [86] introduced a novel approach to resect a pancreatic adenocarcinoma in the body and tail (RAMPS) to increase the rate of R0 resection and lymph node yield. In a meta-analysis (conventional DP group, n = 150; RAMPS group, n = 135), RAMPS showed a higher R0 resection rate (RR = 2.37, 95% CI [1.19–4.72]; p = 0.01) and more lymph nodes harvested (RR = 1.20, 95% CI [1.02–1.41]; p = 0.02) than conventional DP. The one-year survival rate of the RAMPS group was significantly better than that of the DP group (79.2% [99/125] vs. 64.3% [81/126]; p = 0.02), while the long-term survival benefit was not demonstrated [87]. However, among retrospective studies, Sham et al. [88] included the largest number of patients and showed controversial results that the R0 resection rate and the number of retrieved lymph nodes were higher in the conventional DP group than in the RAMPS group. Most retrospective studies showed a higher R0 resection rate and a higher number of retrieved lymph nodes in the RAMPS group than in the conventional DP group, although the benefit of survival was not demonstrated (Table 8) [88-93].

RAMPS is a safe and effective procedure for pancreatic body or tail cancer. However, it does not lead to a better survival than conventional DP. Therefore, the technical approach to pancreatosplenectomy could be selected based on the surgeon’s experience and comfort. RAMPS could be considered for curative resection of selected patients.

Gastrojejunostomy as bypass surgery

KQ 9: Is prophylactic bypass gastrojejunostomy necessary in cases of unresectable pancreatic cancer without gastric outlet obstruction?
Recommendation 9: Bypass gastrojejunostomy is not recommended in patients with unresectable pancreatic cancer without gastric outlet obstruction
(Strength of recommendation: Not recommend; Level of evidence: Low)
Comments: A patient with unresectable pancreatic cancer found during laparotomy traditionally undergoes a prophylactic bypass gastrojejunostomy. Two old RCTs and meta-analysis
showed that prophylactic gastric bypass surgery in cases of unresectable pancreatic cancer was effective in preventing gastric outlet obstruction without serious complications [94-96]. However, with recent advances in endoscopic techniques, surgical bypass has become questionable. In a recently published meta-analysis, endoscopic stent was found to have benefits of a quicker resumption of oral intake and a reduced inpatient hospital stay. However, this was balanced by an increase in the recurrence of symptoms and the need for further intervention [97]. Williamsson et al. [98] have introduced a wait-and-see strategy considering the higher morbidity and longer postoperative stay after surgical bypass. Patients without gastric outlet obstruction could not undergo prophylactic bypass.

For patients with pancreatic cancer without gastric outlet obstruction, the effect of prophylactic bypass is controversial. However, for patients with gastric outlet obstruction, endoscopic stent insertion could be performed as it is associated with lower morbidity and shorter hospital stay than surgical bypass.

Pancreatectomy in case of pathologically proven para-aortic lymph node metastasis

KQ 10: Is pancreatectomy beneficial in cases of pancreatic cancer with pathologically proven para-aortic lymph node metastasis in intraoperative frozen biopsy?

Recommendation 10: Recommendation to perform pancreatectomy in cases of pancreatic cancer with pathologically proven para-aortic lymph node metastasis in intraoperative frozen biopsy is withheld

(Strength of recommendation: Inconclusive; Level of evidence: Very low)

Comments: In general, para-aortic lymph node metastasis is considered a distant metastasis and contraindication for pancreatic resection. However, some pancreatic cancer patients with para-aortic lymph node metastasis have been reported to have longer survival than expected after pancreatectomy. However, no study has compared survival outcomes between pancreatectomy and non-pancreatectomy groups for patients with intraoperatively pathologically proven positive para-aortic lymph nodes and curatively resectable main pancreatic tumor. Previously published studies showed that the median survival of patient with intraoperatively pathologically proven para-aortic lymph node was 5–9 months, significantly worse than that of patients with negative para-aortic lymph node [99,100]. However, recently published studies showed improved median survival of patients with pathologically proven para-aortic lymph nodes in frozen biopsy. Multivariate analysis demonstrated that adjuvant chemotherapy, but not para-aortic lymph node metastasis, was a significant prognostic factor [101-103]. In meta-analyses, although para-aortic lymph node metastasis is associated with decreased survival in pancreatic cancer, based on the finding that those who underwent pancre-
Hepatic oligometastasis

KQ 11: Is hepatic resection beneficial in cases of pancreatic cancer with hepatic oligometastasis?

Recommendation 11: Recommendation to perform hepatic resection in cases of pancreatic cancer with hepatic oligometastasis is withheld (Strength of recommendation: Inconclusive; Level of evidence: Very low)

Comments: The prognosis of patients with liver metastasis from pancreatic cancer is generally regarded as dismal and hepatic resection is not recommended. However, in highly selected patients, hepatectomy showed a survival benefit. Hackert et al. [107] showed that the median survival was 12.3 months and the 5-year survival rate was 8.1% after hepatectomy for oligometastasis. On the other hand, Zanini et al. [108] showed that the median survival of patients who underwent hepatectomy for oligohepatic metastasis was only 9.1 months. Dünschede et al. [109] reported that for patients with metachronous hepatic oligometastasis, hepatectomy showed significantly better median survival than chemotherapy (31 months vs. 11 months). A meta-analysis found that for patients with synchronous hepatic oligometastasis, hepatectomy showed significantly better 1- or 3-year survival than non-resection [110].

Considering the increased number of reports showing improved survival after hepatectomy for hepatic oligometastasis, it is worthwhile to perform curative intended hepatectomy. However, further RCTs are needed to investigate indications for hepatectomy and prognostic factors associated with hepatectomy.

Induction chemotherapy and conversion surgery for locally advanced pancreas cancer

KQ 12: Is conversion surgery beneficial in cases of LAPC?

Recommendation 12: Conversion surgery after induction chemotherapy could be considered in cases of LAPC (Strength of recommendation: Conditional; Level of evidence: Low)

Comments: LAPC has been generally considered to be an unresectable disease. Historically, it was considered a continuum of metastatic disease due to rapid progression of occult metastasis. However, an increasing number of patients with LAPC who respond favorably to induction chemotherapy undergo surgical resection. Most published studies including two RCTs showed improvement of survival in conversion surgery after induction chemotherapy for LAPC [111-116]. Meta-analyses also showed significantly better survival in the conversion surgery group than in the non-surgery group [117,118]. However, evaluation of resectability of pancreatic cancer after induction chemotherapy is challenging. In addition, several indications do not have consensus, such as patients with complete or partial response according to RECIST classification (ver 1.1) after neoadjuvant chemotherapy, after multidisciplinary discussion, after diagnostic laparoscopy, and so on.

Conversion surgery after induction chemotherapy for LAPC could be considered in highly selected patients and should be considered in individual cases. Further studies are needed to investigate indications for resection after induction chemotherapy and effective chemotherapy protocols.

Artery first approach

KQ 13: Is artery first approach in pancreaticoduodenectomy (AFA-PD) beneficial in cases of PHC?

Recommendation 13: Recommendation to perform AFA-PD in cases of PHC is withheld (Strength of recommendation: Inconclusive; Level of evidence: Very low)

Comments: SMA, the most common site of a positive margin following PD, is often the last and the most challenging one to dissect, typically after division of the neck of the pancreas. AFA-PD aims to determine the resectability before the point of no return (transsection of the pancreatic neck or bile duct division) to reduce intraoperative blood loss by early control of blood inflow into the pancreatic head and to increase the R0 resection rate and complete dissection of the connected tissues around the SMA. Despite the above theoretical benefits of this procedure, evidence for its clinical and oncological benefits is sparse. Most published reports of AFA-PD showed less bleeding [70,119,120] but no difference in operation time [70,120-122] or postoperative complications [70,119-122]. However, there was no significant difference in R0 resection rate and the 5-year
### Table 9. Summary of retrospective studies comparing artery first approach in pancreaticoduodenectomy (AFA-PD) and conventional pancreaticoduodenectomy (C-PD)

| Author                  | Comparison group | Number | Op time (min) | p-value | Blood loss (mL) | p-value | R0 rate (%) | p-value | LN harvest (n) | p-value | Morbidity (%) | p-value | Survival (%) | p-value |
|-------------------------|------------------|--------|---------------|---------|-----------------|---------|--------------|---------|----------------|---------|---------------|---------|--------------|---------|
| Kurosaki et al. [121]   | C-PD             | 35     | 526           | 0.651   | 1,352           | 0.814   | 71.4         | 1.00    | N/A            | 42.9    | 0.352         | 17.1∗   | 0.016        |
|                         | AFA-PD           | 40     | 516           |         | 1,307           | 0.814   | 72.5         |         | N/A            | 30.0    | 0.352         | 52.8    |             |
| Aimoto et al. [70]      | C-PD             | 19     | 481           | NS      | 1,568           | < 0.05  | 68           | NS      | 3.4            | < 0.01 | 10            | NS      | 20           |
|                         | AFA-PD           | 19     | 490           |         | 490             | 0.051   | 74           | NS      | 7.9            |         | 20            |         |
| Hirono et al. [119]     | C-PD             | 30     | 371           | 0.007   | 502             | 0.023   | 86.7         | 0.045   | 23.5           | 0.919   | 10            | 0.386   | N/A          | 0.021   |
|                         | AFA-PD           | 28     | 417           |         | 313             | 100     | 80.0         |         | 2            | 23      | 17.9          |         |
|                         | C-PD             | 28     | 452           | 0.210   | 920             | 0.003   | 85.7         | 0.565   | 26             | 0.668   | 17.9          | 0.634   | N/A          | 0.260   |
| Pedziwiatr et al. [122] | C-PD             | 19     | 425           | 0.13    | 392             | 0.33    | 63.2         | 0.84    | 139            | 0.03    | 63.2          | 0.84    | N/A          | N/A     |
|                         | AFA-PD           | 12     | 467           |         | 408             | 66.7    |             |         | 19.3           |         | 66.7          |         |
| Wang et al. [120]       | C-PD             | 39     | 384           | 0.014   | 756             | 0.043   | 82.1         | 0.534   | N/A            |         | 46.2          | 0.603   | N/A          | N/A     |
|                         | AFA-PD           | 38     | 313           |         | 534             | 83.3    |             |         | N/A            |         | 41.0          |         |

Op, operation; LN, lymph node; N/A, not available; NS, not significant.

∗Three-year survival rate; †2-year survival rate; ‡resectable pancreas cancer; §borderline resectable cancer.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**AUTHOR CONTRIBUTIONS**

Seung Eun Lee, Sung-Sik Han, Chang Moo Kang, Wooil Kwon, Kwang Yeol Paik, Ki Byung Song, Jae Do Yang, Jun Chul Chung, Chi-Young Jeong, Sun-Whe Kim

**ORCID**

Seung Eun Lee, https://orcid.org/0000-0003-1830-9666

Sung-Sik Han, https://orcid.org/0000-0001-7047-7961

Chang Moo Kang, https://orcid.org/0000-0002-5382-4658

Wooil Kwon, https://orcid.org/0000-0002-4827-7805

Kwang Yeol Paik, https://orcid.org/0000-0003-1912-9173

Ki Byung Song, https://orcid.org/0000-0001-5422-5481

Jae Do Yang, https://orcid.org/0000-0001-9701-7666

Jun Chul Chung, https://orcid.org/0000-0002-8996-2630

Chi-Young Jeong, https://orcid.org/0000-0003-4121-6695

Sun-Whe Kim, https://orcid.org/0000-0001-6315-6019

**REFERENCES**

1. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-350.

2. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v56-v68. Erratum in: Ann Oncol 2017;28 Suppl 4:iv167-iv168.

3. Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, et al. Clinical Practice Guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas 2020;49:326-335.

4. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, version 2.2021, NCCN Table 9.

**SUMMARY**

Survival rate could not be evaluated due to a short follow-up period (Table 9) [70,119-122]. Recently, Sabater et al. [123] have performed a RCT of patients with periampullary cancers and found no difference in R0 resection rate. Therefore, although AFA-PD is a feasible procedure, the benefit of this procedure such as improvement of resectability and survival has not been proven.
Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw 2021;19:439–457.

5. Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea. Korean clinical practice guideline for pancreatic cancer 2021: a summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. Pancreatology 2021;21:1326-1341.

6. Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

7. Kim SY, Park JE, Lee YJ, Seo HY, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:408–414.

8. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013–1020.

9. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–536.

10. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 1: performance, usefulness and aims for improvement. CMAJ 2010;182:1045–1052.

11. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ 2010;182:E472–E478.

12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–926.

13. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ 2008;336:995–998.

14. Sell NM, Fong ZV, Del Castillo CF, Qadan M, Warshaw AL, Chang D, et al. Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann Surg Oncol 2018;25:1009–1016.

15. Schnellдорfer T, Gagnon AI, Birkett RT, Reynolds G, Murphy KM, Jenkins RL. Staging laparoscopy in pancreatic cancer: a potential role for advanced laparoscopic techniques. J Am Coll Surg 2014;218:1201–1206.

16. Ahmed SI, Bochkarev V, Oleynikov D, Sasson AR. Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A 2006;16:458–463.

17. Contreras CM, Stanelle EF, Mansour J, Hinshaw JL, Rikkers LF, Retnammell R, et al. Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma. J Surg Oncol 2009;100:663–669.

18. Paracha M, Van Orden K, Patts G, Tseng J, McAneny D, Sachs T. Opportunity lost? Diagnostic laparoscopy in patients with pancreatic cancer in the national surgical quality improvement program database. World J Surg 2019;43:937–943.

19. Yamamura K, Yamashita YI, Yamao T, Kuroda E, Eto T, Kitano Y, et al. Efficacy of staging laparoscopy for pancreatic cancer. Anticancer Res 2020;40:1023–1027.

20. Ta R, O’Connor DB, Sulistijjo A, Chung B, Conlon KC. The role of staging laparoscopy in resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis. Dig Surg 2019;36:251–260.

21. De Rosa A, Cameron IC, Gomez D. Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford) 2016;18:13–20.

22. Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325–337.

23. Choi M, Hwang HK, Rho SY, Lee WJ, Kang CM. Comparing laparoscopic and open pancreaticoduodenectomy in patients with pancreatic head cancer: oncologic outcomes and inflammatory scores. J Hepatobiliary Pancreat Sci 2020;27:124–131.

24. Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg 2014;260:633–638; discussion 638–640.

25. Girgis MD, Zenati MS, King JC, Hamad A, Zureikat AH, Zeh HJ, et al. Oncologic outcomes after robotic pancreatic resections are not inferior to open surgery. Ann Surg 2021;274:e262–e268.

26. Kuesters S, Chikhladze S, Makowiec F, Sick O, Fichtner-Feigl S, Hopf UT, et al. Oncological outcome of laparoscopically assisted pancreate-duodenectomy for ductal adenocarcinoma in a retrospective cohort study. Int J Surg 2018;55:162–166.

27. Staufler JA, Coppola A, Villacreses D, Mody K, Johnson E, Li Z, et al. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Surg Endosc 2017;31:2233–2241.

28. Zhou W, Jin W, Wang D, Lu C, Xu X, Zhang R, et al. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Cancer Commun (Lond) 2019;39:66.

29. Adam MA, Choudhury K, Dinan MA, Reed SD, Scheri RP, Blazer DG 3rd, et al. Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients. Ann Surg 2015;262:372–377.

30. Jiang YL, Zhang RC, Zhou YC. Comparison of overall survival and perioperative outcomes of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. J Natl Compr Canc Netw 2019;17:2023–2040.

31. Peng L, Zhou Z, Cao Z, Wu W, Xiao W, Cao J. Long-term oncological outcomes in laparoscopic versus open pancreaticoduodenectomy for pancreatic cancer: a systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A 2019;29:759–769.

32. Yin Z, Jian Z, Hou B, Jin H. Surgical and oncological outcomes of laparoscopic versus open pancreaticoduodenectomy in patients with pancreatic duct adenocarcinoma. Pancreas 2019;48:861–867.

33. Chen K, Zhou Y, Jin W, Zhu Q, Lu C, Niu N, et al. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncological outcomes and long-term survival. Surg Endosc 2020;34:1948–1958.

https://doi.org/10.14701/ahbps.22-009
34. Lee SH, Kang CM, Hwang HK, Choi SH, Lee WJ, Chi HS. Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes. Surg Endosc 2014;28:2848-2855.

35. Sulpicie L, Farges O, Goutte N, Bendersky N, Dokmak S, Sauvanet A, et al. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: time for a randomized controlled trial? Results of an all-inclusive national observational study. Ann Surg 2015;262:868-873; discussion 873-874.

36. van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, et al. Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study. Ann Surg 2019;269:10-17.

37. Zhang M, Fang R, Mou Y, Chen R, Xu X, Zhang R, et al. LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution. BMC Gastroenterol 2015;15:182.

38. Anderson KL Jr, Adam MA, Thomas S, Roman SA, Sosa JA. Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. Am J Surg 2017;213:601-605.

39. Kantor O, Bryan DS, Talamonti MS, Lutfi W, Sharpe S, Winchester DJ, et al. Laparoscopic distal pancreatectomy for cancer provides oncologic outcomes and overall survival identical to open distal pancreatectomy. J Gastrointest Surg 2017;21:1620-1625.

40. Riviere D, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MG, Davidson BR, et al. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Cochrane Database Syst Rev 2016;4:CD011391.

41. Farnell MB, Pearson RK, Sarr MG, DiMango EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatectoduodenectomy with pancreaticoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-628; discussion 628-630.

42. Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, et al. Standard versus extended lymphadenectomy in radical pancreatectoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012;19:230-241.

43. Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 2014;259:656-664.

44. Jang JY, Kang JS, Han Y, Heo JS, Choi SH, Choi DW, et al. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci 2017;24:426-433.

45. Ignjatovic I, Knezevic S, Knezevic D, Dugalic V, Micev M, Matic S, et al. Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma. J BUON 2017;22:232-238.

46. Svoronos C, Tsoufals G, Katsourakis A, Noussios G, Chatzitheoklitos E, Marakis NG. Role of extended lymphadenectomy in the treatment of pancreatic head adenocarcinoma: review and meta-analysis. ANZ J Surg 2014;84:706-711.

47. Wang W, He Y, Wu L, Ye L, Yao L, Tang Z. Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis. Pancreatology 2019;19:1074-1080.

48. Michalski CW, Kleeff J, Wente MN, Diener MK, Büchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreatoduodenectomy for pancreatic cancer. Br J Surg 2007;94:265-273.

49. Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg 2016;103:179-191.

50. Peng C, Zhou D, Meng L, Cao Y, Zhang H, Pan Z, et al. The value of combined vein resection in pancreatoduodenectomy for pancreatic head carcinoma: a meta-analysis. BMC Surg 2019;19:84.

51. Bell R, Ao BT, Ironside N, Bartlett A, Windsor JA, Pandanaboyina S. Meta-analysis and cost effective analysis of portal-superior mesenteric vein resection during pancreatoduodenectomy: impact on margin status and survival. Surg Oncol 2017;26:53-62.

52. Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol 2014;40:371-378.

53. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 2012;36:884-891.

54. Amano H, Miura F, Toyota N, Wada K, Katoh K, Hayano K, et al. Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer? J Hepatobiliary Pancreat Sci 2009;16:850-857.

55. Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. Arterial en bloc resection for pancreatic carcinoma. Br J Surg 2011;98:86-92.

56. Bachellier P, Rosso E, Lucescu I, Oussoultzoglou E, Tracey J, Pessaux P, et al. Is the need for an arterial resection a contraindication to Pancreatic resection for locally advanced pancreatic adenocarcinoma? A case-matched controlled study. J Surg Oncol 2011;103:75-84.

57. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeper Y, Büchler MW, et al. Arterial resection during pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 2011;254:882-893.

58. Małczak P, Sierżęga M, Stefura T, Kacprzyk A, Droś J, Skomarowska O, et al. Arterial resections in pancreatic cancer - systematic review and meta-analysis. HPB (Oxford) 2020;22:961-968.

59. Haines M, Chua TC, Jamieson NB, Mittal A, Gill AJ, Samra JS. Pancreatectoduodenectomy with arterial resection for locally advanced pancreatic cancer of the head: a systematic review. Pancreas 2020;49:621-628.

60. Wu X, Tao R, Lei R, Han B, Cheng D, Shen B, et al. Distal pancreatectomy combined with celiac axis resection in treatment of carcinoma of the body/tail of the pancreas: a single-center experience. Ann Surg Oncol 2010;17:1359-1366.

61. Beane JD, House MG, Pitt SC, Kilbane EM, Hall BL, Parmar AD, et al. Yonsei criteria: long-term (>median 3 years) oncologic outcomes. Ann Surg Oncol 2010;17:1359-1366.
al. Distal pancreatectomy with celiac axis resection: what are the added risks? HPB (Oxford) 2015;17:777-784.
62. Yamamoto Y, Sakamoto Y, Ban D, Shimada K, Esaki M, Nara S, et al. Is celiac axis resection justified for T4 pancreatic body cancer? Surgery 2012;151:61-69.
63. Peters NA, Javed AA, Cameron JL, Makary MA, Hirose K, Pawlik TM, et al. Modified Appleby procedure for pancreatic adenocarcinoma: does improved neoadjuvant therapy warrant such an aggressive approach? Ann Surg Oncol 2016;23:3757-3764.
64. Gong H, Ma R, Gong J, Cai C, Song Z, Xu B. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3061.
65. Nigri G, Petruchiani N, Belloni E, Lucarini A, Aurello P, D’Angelo F, et al. Distal pancreatectomy with celiac axis resection: systematic review and meta-analysis. Cancers (Basel) 2021;13:1967.
66. Storkholm JH, Burgdorf SK, Hansen CP. Distal pancreas-coeliac axis resection with preoperative selective embolization of the coeliac axis: a single high-volume centre experience. Langenbecks Arch Surg 2020;405:635-645.
67. Kawabata Y, Tanaka T, Nishi T, Monna H, Yano S, Tajima Y. Appraisal of a total meso-pancreato-duodenal excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012;38:574-579.
68. Xu J, Tian X, Chen Y, Ma Y, Liu C, Tian L, et al. Total mesopancreas excision for the treatment of pancreatic head cancer. J Cancer 2017;8:3575-3584.
69. Sugiyama M, Suzuki Y, Nakazato T, Yokoyama M, Kogure M, Abe N, et al. Intestinal derotation procedure for facilitating pancreato-duodenectomy. Surgery 2016;159:1325-1332.
70. Aimoto T, Mizutani S, Kawano Y, Matsushita A, Yamashita N, Suzuki H, et al. Left posterior approach pancreaticoduodenectomy with total mesopancreas excision and circumferential lymphadenectomy around the superior mesenteric artery for pancreatic head carcinoma. J Nippon Med Sch 2013;80:438-445.
71. Srinarmwong C, Luechakiettisak P, Prasitvilai W. Standard whipple’s operation versus pylorus preserving pancreaticoduodenectomy: a randomized controlled trial study. J Med Assoc Thai 2008;91:693-698.
72. Tani M, Kawai M, Hirono S, Ina S, Miyazawa M, Fujita Y, et al. Pylorus-preserving pancreaticoduodenectomy versus conventional pancreaticoduodenectomy for pancreatic adenocarcinoma. Surg Today 2009;39:219-224.
73. Kawai M, Tani M, Hirono S, Okada K, Miyazawa M, Yamaue H. Pylorus-preserving pancreaticoduodenectomy offers long-term outcomes similar to those of pylorus-preserving pancreaticoduodenectomy: results of a prospective study. World J Surg 2014;38:1476-1483.
74. Iqbal N, Lovegrove RE, Tilney HS, Abraham AT, Bhattacharya S, Tekkis PP, et al. A comparison of pancreaticoduodenectomy with pylorus preserving pancreaticoduodenectomy: a meta-analysis of 2822 patients. Eur J Surg Oncol 2008;34:1237-1245.
75. Yang C, Wu HS, Chen XL, Wang CY, Gou SM, Xiao J, et al. Pylorus-preserving versus pylorus-resecting pancreaticoduodenectomy for periampullary and pancreatic carcinoma: a meta-analysis. PLoS One 2014;9:e90316.
76. Hütten JF, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Büchler MW, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2016;2:CD006053.
77. Klaiber U, Probst P, Hütten JF, Bruckner T, Strobel O, Diener MK, et al. Randomized trial of pylorus-preserving vs. pylorus-resecting pancreaticoduodenectomy: long-term morbidity and quality of life. J Gastrointest Surg 2020;24:341-352.
78. Fatima J, Schnellstorfer T, Barton J, Wood CM, Wiste HJ, Smyrk TC, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg 2010;145:167-172.
79. Pang TC, Wilson O, Argueta MA, Hugh TJ, Chou A, Samra JS, et al. Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility. Pathology 2014;46:188-192.
80. Mathur A, Ross SB, Liberice K, Kurian T, Vice M, Toomey P, et al. Margin status impacts survival after pancreaticoduodenectomy but negative margins should not be pursued. Am Surg 2014;80:353-360.
81. Nitschke P, Volk A, Welsh T, Hackl J, Reissfelder C, Rahbari M, et al. Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients. Ann Surg 2017;265:1219-1225.
82. Dikmen K, Kerem M, Bostanci H, Sare M, Ekinci O. Intra-operative frozen section histology of the pancreatic resection margins and clinical outcome of patients with adenocarcinoma of the head of the pancreas undergoing pancreaticoduodenectomy. Med Sci Monit 2018;24:4905-4913.
83. Crippa S, Guarnieri G, Belfiori G, Partelli S, Pagnanelli M, Gasparini G, et al. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival following pancreato-duodenectomy for pancreatic cancer. Eur J Surg Oncol 2020;46:1524-1531.
84. Barreto SG, Pandanaboyana S, Ironside N, Windsor JA. Does revision of resection margins based on frozen section improve overall survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma? A meta-analysis. HPB (Oxford) 2017;19:573-579.
85. Petruchiani N, Nigri G, Debs T, Giannini G, Sborlini E, Antolino L, et al. Frozen section analysis of the pancreatic margin during pancreatoduodenectomy for periampullary and pancreatic carcinoma: a meta-analysis. Pancreatology 2016;16:1037-1043.
86. Strasberg SM, Drebbin JA, Linehan D. Randomized trial of pylorus-preserving versus pylorus-resecting pancreaticoduodenectomy: a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology 2016;16:1037-1043.
87. Pang TC, Wilson O, Argueta MA, Hugh TJ, Chou A, Samra JS, et al. Frozen section of the pancreatic neck margin in pancreatoduodenectomy: a meta-analysis and systematic review. Pancreatology 2016;16:1037-1043.
creatosplenectomy for pancreatic cancer, a dual-institutional analysis. Chin Clin Oncol 2020;5:94. Erratum in: Chin Clin Oncol 2020;9:72.
89. Abe T, Ohuchida K, Miyasaka Y, Ohtsuka T, Oda Y, Nakamura M. Comparison of surgical outcomes between radical antegrade modular pancreaticosplenectomy (RAMPS) and standard retrograde pancreaticosplenectomy (SPRS) for left-sided pancreatic cancer. World J Surg 2016;40:2267-2275.
90. Grossman JG, Fields RC, Hawkins WG, Strasberg SM. Single institution results of radical antegrade modular pancreaticosplenectomy for adenocarcinoma of the body and tail of pancreas in 78 patients. J Hepatobiliary Pancreat Sci 2016;23:432-441.
91. Kim EY, You YK, Kim DG, Hong TH. Initial experience with radical antegrade modular pancreaticosplenectomy in a single institution. Ann Surg Treat Res 2016;91:29-36.
92. Kawabata Y, Hayashi H, Kaji S, Fujii Y, Nishi T, Tajima Y. Laparoscopic versus open radical antegrade modular pancreaticosplenectomy with artery-first approach in pancreatic cancer. Langenbecks Arch Surg 2020;405:647-656.
93. Kim HS, Hong TH, You YK, Park JS, Yoon DS. Radical antegrade modular pancreaticosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study. Surg Today 2021;51:1775-1786.
94. Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999;230:322-328; discussion 328-330.
95. Wong YT, Brans DM, Munson L, Sanders L, Heiss F, Chase M, et al. Gastric outlet obstruction secondary to pancreatic cancer: surgical vs endoscopic palliation. Surg Endosc 2002;16:310-312.
96. Gurusamy KS, Kumar S, Davidson BR. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev 2013;2013:CD008533.
97. Upchurch E, Ragusa M, Cirocchi R. Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction. Cochrane Database Syst Rev 2018;5:CD012506.
98. Williamson C, Wennerblom J, Tingstedt B, Jonsson C. A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB (Oxford) 2016;18:107-112.
99. Doi R, Kami K, Ito D, Fujimoto K, Kawaguchi Y, Wada M, et al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg 2007;31:147-154.
100. Schwarz L, Lupinacci RM, Svreck M, Lesurtel M, Bubenheim M, Vuarnesson H, et al. Para-aortic lymph node sampling in pancreatic head adenocarcinoma. Br J Surg 2014;101:530-538.
101. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Yuasa Y, Sueda T. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg 2010;34:1900-1907.
102. Shio M, Murakami Y, Motoi F, Sato S, Matsumoto I, Kawai M, et al. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. J Gastroenterol 2015;50:694-702.
103. Hempel S, Plodeck V, Mierke F, Distler M, Aust DE, Saeger HD, et al. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection. Sci Rep 2017;7:6688.
104. Agalianos C, Gouveas N, Papaparaskeva K, Dervenis C. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. HPB (Oxford) 2016;18:633-641.
105. Païella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2016;42:616-624.
106. Asaoka T, Miyamoto A, Maeda S, Hama N, Tsuje M, Ikeda M, et al. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. Hepatobiliary Pancreat Dis Int 2018;17:75-80.
107. Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 2017;43:358-363.
108. Zanini N, Lombardi M, Masetti M, Giordano M, Landolfi G, Jovine E. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg 2015;67:19-25.
109. Dünschede F, Will L, von Langsdorf C, Möhler M, Galle PR, Otto G, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res 2010;44:209-213.
110. Yu X, Gu J, Fu D, Jin C. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. Int J Surg 2017;48:149-154.
111. Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cuffe A, Francois E, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol 2015;22:295-301.
112. Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, et al. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 2012;7:28.
113. Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M, Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol 2014;20:9374-9383.
114. Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol 2015;111:1028-1034.
115. Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 2019;270:340-347.
116. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy With FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1020-1027.
117. Doi R, Imamura M, Hosotani R, Imazumii T, Hatori T, Takasaki K, et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today 2008;38:1021-1028.
118. Gurusamy KS, Kumar S, Davidson BR, Fusai G. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev 2014;(2):CD010244.

119. Hirono S, Kawai M, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, et al. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2017;1:208-218.

120. Wang M, Zhang H, Zhu F, Peng F, Wang X, Shen M, et al. Pancreateicoduodenectomy for borderline resectable pancreatic head cancer with a modified artery-first approach technique. Hepatobiliary Pancreat Dis Int 2017;16:215-221.

121. Kurosaki I, Minagawa M, Takano K, Takizawa K, Hatakeyama K. Left posterior approach to the superior mesenteric vascular pedicle in pancreaticoduodenectomy for cancer of the pancreatic head. JOP 2011;12:220-229.

122. Pędziwiatr M, Pisarska M, Małczak P, Major P, Wierdak M, Radkowiak D, et al. Laparoscopic uncinate process first pancreateoduodenectomy-feasibility study of a modified ‘artery first’ approach to pancreatic head cancer. Langenbecks Arch Surg 2017;402:917-923.

123. Sabater L, Cugat E, Serrablo A, Suarez-Artacho G, Diez-Valladares I, Santoyo-Santoyo J, et al. Does the artery-first approach improve the rate of R0 resection in pancreateoduodenectomy?: A multicenter, randomized, controlled trial. Ann Surg 2019;270:738-746.